Company news
Lixte Biotechnology Holdings, Inc. news in 2024
Lixte Biotechnology Holdings, Inc.'s news releases, calls and decks from 2024, newest first.
LIXTE Receives U.S. Patent Issue Notification for Immune Oncology
September 3, 2024
First Patient Dosed with LIXTE’s LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company
August 25, 2024
LIXTE Biotechnology Provides Update On Recent Activities and Developments
August 18, 2024
LIXTE Biotechnology Holdings to Present at Two Investor Conferences
August 14, 2024
LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical Trial
June 13, 2024
LIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical Officer
June 2, 2024
LIXTE Biotechnology Holdings Provides Update on Recent Activities
May 19, 2024
LIXTE Biotechnology Co-Sponsoring International Scientific Conference on “Therapeutic Over-Activation in Cancer”
May 7, 2024
LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments
March 20, 2024
LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI
February 25, 2024
First Patient Dosed with LIXTE’s LB-100 and GSK’s Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial
January 28, 2024